<DOC>
	<DOCNO>NCT02321293</DOCNO>
	<brief_summary>The purpose study assess safety tolerability curcumin combination EGFR-TKIs select patient advanced non-resectable mutant EGFR NSCLC .</brief_summary>
	<brief_title>A Open-label Prospective Cohort Trial Curcumin Plus Tyrosine Kinase Inhibitors ( TKI ) EGFR -Mutant Advanced NSCLC</brief_title>
	<detailed_description>This phase 1 open prospective cohort study assess safety feasibility use curcumin conjunction EGFR-TKI patient advance NSCLC . The investigator use enhance bioavailable formulation curcumin ( CURCUViva TM 80 mg/ 1 capsule per day ) approve licensed Health Canada ( NPN 80027414 ) show 2-3 time higher curcumin concentration blood compare previous clinical trial . As primary objective , investigator recruit 20 patient duration 8 week monitor adverse effect accord National Cancer Institute Common Terminology Criteria.Exploratory objective would include assess change health-related quality life use standardized FACT-L questionnaire evaluate anti-inflammatory property curcumin measure CRP . If tolerable safety data obtain , expand phase II trial design .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Newly diagnose patient treatment histologically confirm advanced EGFRmutant NSCLC define unresectable stage 3A , stage 3B stage 4 . The EGFR mutation analysis must perform prior enrolment trial ( i.e. , patient consent ) . Any EGFR mutationpositive result must document analysis mutation perform use JGH local test methodology . Receiving concurrent EGFRTKI therapy . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 03 Symptomatic brain metastasis . Patients receive investigational agent . Patients use nonvitamin mineral regular natural health product , include Chinese Herbs . Incapacity understand sign write informed consent document English/French . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>curcumin</keyword>
	<keyword>lung cancer</keyword>
	<keyword>TKI</keyword>
</DOC>